Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non–Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care
Lee, Ji‐Hyun , Fulp, William J. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George P., Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Malafa, Mokenge P. , Jacobsen, Paul B. , Tanvetyanon, Tawee , Brown, Richard H, Abesada-Terk, Guillermo, Sharp, Philip V, Malafa, Mokenge, Brown, Richard H., Markham, Merry J

Journal of Oncology Practice | July 17, 2015 | Volume: 11 | Issue: 4 | Pages: 332-337

10.1200/jop.2014.001750 | PMID 25991639 Get It

In this study, academic practice status and treatment year predicted use of adjuvant cisplatin-based chemotherapy.
Epidermal reference genes at the forefront of data interpretation
Mound, Abdallah, Malaisse, Jérémy, Vuyst, Évelyne De , Hayez, Aurélie, Rouvroit, Catherine Lambert de , Pittelkow, Mark R. , Poumay, Yves

Experimental Dermatology | July 17, 2015 | Volume: 24 | Issue: 10 | Pages: 738-739

10.1111/exd.12811 | PMID 26186391 Get It

Endovascular Repair of Saccular Ascending Aortic Aneurysm After Orthotopic Heart Transplantation Using an Investigational Zenith Ascend Stent-Graft
Pochettino, Alberto , Mendes, Bernardo C. , Pulido, Juan N. , Gloviczki, Péter , Pulido, Juan, Oderich, Gustavo S. , Roeder, Blayne A. , Gloviczki, Péter

Journal of Endovascular Therapy | July 17, 2015 | Volume: 22 | Issue: 4 | Pages: 650-654

10.1177/1526602815593537 | PMID 26112175 Get It

Purpose: To report the use of an investigational stent-graft to treat an ascending aortic aneurysm in a patient with a heart transplant. Case Report: A 48-year-old man presented with a 3.5×1.5-cm saccular aneurysm in the mid anterior ascending aorta, abutting the sternum. The patient’s history was notable for placement of a left ventricular assist device followed by orthotopic heart transplantation 2 years prior to treat end-stage familial dilated cardiomyopathy. Under compassionate use, a custom-designed ascending aortic stent-graft (Zenith Ascend) was successfully delivered via an 18-F system and deployed just distal to the origin of the left main coronary artery under pulmonary artery catheter–guided rapid ventricular pacing. The patient was discharged the next day, and 6-month follow-up was unremarkable. Imaging at 5 months showed an excluded aneurysm sac with no endoleak or migration. Conclusion: The ideal ascending aortic stent-graft should be low profile, conformable to the arch anatomy, with short tip delivery system and a stepwise deployment mechanism that allows precise placement relative to the ostia of the coronary arteries and the innominate artery. This case illustrates the advancement of endovascular techniques to the most challenging segment of the aorta to decrease morbidity and mortality in high-risk patients.
Risk factors for hydrocephalus requiring external ventricular drainage in patients with intraventricular hemorrhage
Hughes, Joshua , Puffer, Ross C. , Rabinstein, Alejandro A.

Journal of Neurosurgery | July 17, 2015 | Volume: 123 | Issue: 6 | Pages: 1439-1446

10.3171/2015.1.jns142391 | PMID 26186024 Get It

OBJECT External ventricular drainage (EVD) after intraventricular hemorrhage (IVH) without symptomatic hydrocephalus is controversial. The object of this study was to examine indicators or the timeframe for hydrocephalus in patients not immediately treated with EVD after IVH. METHODS Records from 2007 to 2014 were searched for “intraventricular hemorrhage” or “IVH.” Inclusion criteria were IVH after intracerebral hemorrhage (ICH), trauma, tumor, or vascular anomalies. Exclusion criteria were IVH with more than minimal subarachnoid hemorrhage, catastrophic ICH, layering IVH only, or hydrocephalus treated immediately with EVD. IVH was measured with the modified Graeb Score (mGS). An mGS of 5 indicates a full ventricle with dilation. Statistics included chi-square, Student’s t-test, and Mann-Whitney tests; receiver operating characteristics; and uni- and multivariate logistic regression. RESULTS One hundred five patients met the criteria; of these, 30 (28.6%) required EVD. Panventricular IVH was the most common pattern (n = 49, 46.7%), with 25 of these patients (51%) requiring EVD. The median mGS was 18 ± 5.4 (range 12–29) and 9 ± 4.5 (range 2–21) in the EVD and No-EVD groups, respectively (p < 0.001). Factors associated with EVD were radiological hydrocephalus at presentation, midline shift > 5 mm, Glasgow Coma Scale (GCS) score < 8, mGS > 13, third ventricle mGS = 5, and fourth ventricle mGS = 5. On multivariate analysis, GCS score < 8 [4.02 (range 1.13–14.84), p = 0.032], mGS > 13 [3.83 (range 1.02–14.89), p = 0.046], and fourth ventricle mGS = 5 [5.01 (range 1.26–22.78), p = 0.022] remained significant. Most patients treated with EVD (n = 25, 83.3%) required it soon after presentation [6.4 ± 3.3 (range 1.5–14) hrs]. The remaining 5 patients (16.7%) had a delayed EVD requirement [70.7 ± 22.7 (range 50–104.5) hrs]. CONCLUSIONS In this study population, the risk for EVD was variable, but greater with mGS > 13, coma, and a dilated fourth ventricle. While the need for EVD occurs within the 1st day after IVH in most patients, a minority require EVD after 48 hours.
Unawareness of Hyposmia in Elderly People With and Without Parkinson's Disease
Shill, Holly A. , Hentz, Joseph G. , Caviness, John N., Driver‐Dunckley, Erika , Jacobson, Sandra A. , Belden, Christine M. , Beach, Thomas G. , Sabbagh, Marwan Noel , Adler, Charles H.

Movement Disorders Clinical Practice | July 17, 2015 | Volume: 3 | Issue: 1 | Pages: 43-47

10.1002/mdc3.12220 | PMID 30363525 Get It

Abstract Background Hyposmia is common in Parkinson's disease (PD) and is also observed with normal aging. It can be ascertained through objective testing, but it is unclear whether patients are aware of deficits and whether this has implications for cognitive status. Methods Subjects in the Arizona Study of Aging and Neurodegenerative Disorders were studied with annual motor and cognitive testing with objective smell testing (University of Pennsylvania Smell Identification Test; UPSIT ) done every third year beginning in 2002. Those with a baseline UPSIT <25th percentile (hyposmia) were studied for presence of unawareness of hyposmia and cognitive status. Results There were 75 subjects with PD and 143 nonparkinsonian controls with hyposmia. Lack of awareness of hyposmia was present in 16% of PD subjects and 47% of those without PD . In PD , there was no increase in unawareness in PD with dementia. In non‐ PD controls, unawareness was correlated with presence of dementia. Unawareness of hyposmia correlated most strongly with the neuropsychiatric tests of learning and memory. In controls without dementia or PD , 48% were unaware. Conclusions Querying patients about anosmia might be useful in parkinsonian disorders without objective testing. However, in elderly controls, it should be followed by objective testing and lack of awareness has implications for worsened cognitive status.
Partial fourier and parallel MR image reconstruction with integrated gradient nonlinearity correction
Tao, Shengzhen , Trzasko, Joshua D. , Shu, Yunhong , Weavers, Paul T., Gray, Erin M. , Bernstein, Matt A. , Huston, John , Bernstein, Matt A

Magnetic Resonance in Medicine | July 17, 2015 | Volume: 75 | Issue: 6 | Pages: 2534-2544

10.1002/mrm.25842 | PMID 26183425 Get It

PurposeTo describe how integrated gradient nonlinearity (GNL) correction can be used within noniterative partial Fourier (homodyne) and parallel (SENSE and GRAPPA) MR image reconstruction strategies, and demonstrate that performing GNL correction during, rather than after, these routines mitigates the image blurring and resolution loss caused by postreconstruction image domain based GNL correction.MethodsStarting from partial Fourier and parallel magnetic resonance imaging signal models that explicitly account for GNL, noniterative image reconstruction strategies for each accelerated acquisition technique are derived under the same core mathematical assumptions as their standard counterparts. A series of phantom and in vivo experiments on retrospectively undersampled data were performed to investigate the spatial resolution benefit of integrated GNL correction over conventional postreconstruction correction.ResultsPhantom and in vivo results demonstrate that the integrated GNL correction reduces the image blurring introduced by the conventional GNL correction, while still correcting GNL‐induced coarse‐scale geometrical distortion. Images generated from undersampled data using the proposed integrated GNL strategies offer superior depiction of fine image detail, for example, phantom resolution inserts and anatomical tissue boundaries.ConclusionNoniterative partial Fourier and parallel imaging reconstruction methods with integrated GNL correction reduce the resolution loss that occurs during conventional postreconstruction GNL correction while preserving the computational efficiency of standard reconstruction techniques. Magn Reson Med 75:2534–2544, 2016. © 2015 Wiley Periodicals, Inc.
Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study
Moreira, Daniel M. , Nickel, J. Curtis , Andriole, Gerald L. , Castro‐Santamaria, Ramiro , Freedland, Stephen J.

The Prostate | July 17, 2015 | Volume: 75 | Issue: 13 | Pages: 1492-1498

10.1002/pros.23041 | PMID 26184556 Get It

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Korecka, Magdalena , Figurski, Michal, Toledo, Jon B. , Blennow, Kaj , Waligórska, Teresa, Brylska, Magdalena, Fields, Leona, Shah, Nirali, Soares, Holly , Dean, Robert A., Vanderstichele, Hugo, Petersen, Ronald C. , Aisen, Paul , Saykin, Andrew J. , Weiner, Michael W. , Trojanowski, John Q. , Shaw, Leslie M. , Initiative, Alzheimer's Disease Neuroimaging, Kang, Ju‐Hee , Zetterberg, Henrik , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 772-791

10.1016/j.jalz.2015.05.003 | PMID 26194312 Get It

AbstractIntroductionWe describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t‐tau, and p‐tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids.MethodsReview publications authored or coauthored by ADNI Biomarker core faculty and selected non‐ADNI studies to deepen the understanding and interpretation of CSF Aβ1–42, t‐tau, and p‐tau181 data.ResultsCSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non‐ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies.DiscussionFurther studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease‐modifying therapeutic trials.
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2
Jack, Clifford R. , Barnes, Josephine , Bernstein, Matt A. , Borowski, Bret, Brewer, James, Clegg, Shona , Dale, Anders M. , Carmichael, Owen , Ching, Christopher R. K. , DeCarli, Charles , Desikan, Rahul S. , Fennema‐Notestine, Christine , Fjell, Anders M. , Fox, Nick C. , Gunter, Jeff, Holland, Dominic , Hua, Xue , Kantarci, Kejal , Krueger, Gunnar, Leung, Kelvin K., Mackin, Scott, Maillard, Pauline , Malone, Ian B. , Mattsson, Niklas , McEvoy, Linda K. , Modat, Marc , Mueller, Susanne G. , Nosheny, Rachel L. , Ourselin, Sébastien , Schuff, Norbert, Senjem, Matthew L. , Simonson, Alix, Thompson, Paul M. , Rettmann, Dan , Vemuri, Prashanthi , Walhovd, Kristine B. , Zhao, Yansong , Zuk, Samantha M., Weiner, Michael W. , DeCarli, Charles , Borowski, Bret J, Zuk, Samantha, Fletcher, Evan M. , Gutman, Boris A , Insel, Philip S. , Killiany, Ronald , Bernstein, Matt A , Jack, Clifford R , Vemuri, Prashanthi , Dale, Anders M , Thompson, Paul M , Senjem, Matthew L , Ching, Christopher R K , Kantarci, Kejal , Fox, Nick C , Maillard, Pauline

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 740-756

10.1016/j.jalz.2015.05.002 | PMID 26194310 Get It

AbstractIntroductionAlzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.MethodsWe review the contributions of the MRI core from present and past cycles of ADNI (ADNI‐1, ‐Grand Opportunity and ‐2). We also review plans for the future‐ADNI‐3.ResultsContributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.DiscussionOver the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.
Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans
Aisen, Paul , Petersen, Ronald C. , Donohue, Michael , Weiner, Michael W. , Initiative, Alzheimer's Disease Neuroimaging, Initiative, Alzheimer's Disease Neuroimaging, Donohue, Michael C

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 734-739

10.1016/j.jalz.2015.05.005 | PMID 26194309 Get It

AbstractIntroductionThis article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project.MethodsClinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors.ResultsThe longitudinal data in ADNI‐2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD).DiscussionPlans for the next phase of the ADNI project include maintaining longitudinal follow‐up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient‐reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease‐modifying agents may be most useful.